Japanese CLL Patients' response to Venetoclax±Rituximab under the microscope

NCT ID NCT06362044

Completed Knowledge-focused Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study in Japan looked at 89 adults with relapsed chronic lymphocytic leukemia (CLL) who took Venetoclax (with or without Rituximab) for 24 months. The main goal was to see how many had undetectable minimal residual disease (uMRD), a sign of deep response. Researchers collected data from routine clinic visits to understand real-world outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Venetoclax (oral tablet) with or without Rituximab (intravenous infusion)
What this could lead to: If successful, this study could help doctors understand how well Venetoclax±Rituximab works in Japanese patients with relapsed CLL, potentially guiding better treatment decisions.
What could go wrong: This is an observational study, not a controlled trial, so results may not prove cause and effect. The small size (89 patients) and focus on Japan may limit how widely findings apply.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA

Contacts and locations

Locations

National Cancer Center Hospital East /ID# 265970

Kashiwa-shi, Chiba, 277-8577, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.